We are live on ! Find out more
OCRX

Ocera Therapeutics
OCRX

Delisted

OCRX was delisted on the 8th of December, 2017.

36 hedge funds and large institutions have $19.2M invested in Ocera Therapeutics in 2016 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 13 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

160% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 5

148% more capital inflows, than outflows

Capital inflows: $4.08M | Capital outflows: $1.64M

39.57% more ownership

Funds ownership: 0% → 39.57% (+40%)

16% more funds holding

Funds holding: 31 → 36 (+5)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
36
Holders Change
+5
Holders Change %
+16.13%
% of All Funds
0.9%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
13
Reduced
5
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

OCRX Hedge Fund Activity: Q4 2016 in Review

36 of the 4,009 institutional investors tracked by Wall St. Rank reported a position in Ocera Therapeutics (OCRX) for Q4 2016, worth a combined $19.2M — down 9.5% from $21.3M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new OCRX positions and 3 closed out — a net gain of 5 holders — while 13 added to existing stakes and 5 trimmed.

The largest buyer was VHCP Management II, adding an estimated $302K. The largest seller was Vanguard Group, cutting an estimated $599K.

  • 36 institutional investors held Ocera Therapeutics (OCRX) as of Q4 2016, up from 31 in Q3 2016.
  • Funds reported $19.2M of Ocera Therapeutics stock for Q4 2016, down 9.5% quarter-over-quarter.
  • 8 funds opened new Ocera Therapeutics positions in Q4 2016 and 3 closed out, a net change of +5 holders.
  • The largest Ocera Therapeutics buyer in Q4 2016 was VHCP Management II, an estimated $302K added.
  • The largest Ocera Therapeutics seller in Q4 2016 was Vanguard Group, an estimated $599K sold.

Based on aggregated 13F filings for Q4 2016.